MEDINDIA
English
हिन्दी
Español
français
中文
Dr. Sabatine is an associate physician in the Cardiovascular MedicineDivision at Brigham and Women's Hospital (BWH), an investigator in theThrombolysis in Myocardial Infarction (TIMI) Study Group, and an assistantprofessor of medicine at Harvard Medical School. Dr. Sabatine's researchfocuses on the diagnosis and treatment of acute coronary syndromes, with aparticular interest in using biomarkers, genetic epidemiology, and proteomicsfor risk stratification. His research endeavors in those fields are supportedby several grants from the National Institutes of Health. Dr. Sabatine hasauthored over 100 original research articles, reviews, editorials, and bookchapters and serves as a manuscript reviewer for several major medicaljournals. Dr. Sabatine has been awarded a Howard Hughes Medical InstituteResearch Fellowship, an ACC Cardiology Fellowship, and the ACC YoungInvestigator Award. He is board certified in Internal Medicine and Cardiologyand is a member of the American Heart Association and a Fellow of the AmericanCollege of Cardiology.
Dr. Morrow is assistant professor of medicine at Harvard Medical School,in the division of cardiovascular medicine at BWH. He was instrumental in thedevelopment of the TIMI Biomarker Program at BWH, and his research at TIMIfocuses on risk stratification and the management of acute coronary syndromes.Dr. Morrow sits on the National Academy of Clinical Biochemistry (NACB)Laboratory Medicine Practice Guidelines Committee on Biochemical CardiacMarkers and leads the clinical section on ACS. He is on the editorial boardsof American Heart Journal, Circulation, Clinical Chemistry, and the Journal ofthe American College of Cardiology and is a Continuing Medical Educationeditor for Circulation. Dr. Morrow is also the editor of "CardiovascularBiomarkers: Pathophysiology and Disease Management" and serves on the ProgramCommittee for the American Heart Association Council on Clinical Cardiology.In addition to being a frequent lecturer, Dr. Morrow has more than 100original reports, reviews, editorials, book chapters, and electronicpublications in his areas of expertise.
About Singulex
Singulex develops and commercializes innovative technology solutions thatenable disease understanding and management for life science researchers andclinicians. Utilizing proprietary quantitative single molecule detectiontechnology, Singulex develops customized biomarker diagnostic systems that candetect and quantify normal and abnormal protein biomarkers in a variety ofbiological samples with extreme sensitivity and accuracy. Singulex iscurrently conducting several pilot studies with academic and moleculardiagnostic partners to validate the company's commercial digital moleculedetection platform, the Erenna(TM) Immunoassay System. Singulex's researchand development facilities are located at the Center for Emerging Technologiesin St Louis, Missouri, and the company's commercial operations are based inHayward, California. To learn more about Singulex, please visit us athttp://www.singulex.com.
SOURCE Singulex Inc.
